Abstract: The present disclosure relates to novel lantibiotics, lantibiotic pharmaceutical compositions, isolated and recombinant lantibiotic-producing bacteria, bacterial pharmaceutical compositions, methods of producing novel lantibiotics from lantibiotic-producing bacteria, and methods of using such lantibiotics, lantibiotic pharmaceutical compositions, and bacterial pharmaceutical compositions to treat gram-positive bacteria infections, including vancomycin resistant enterococci infections, in patients, and to treat food and other objects to avoid gram-positive bacteria contamination.
Type:
Grant
Filed:
October 21, 2019
Date of Patent:
December 28, 2021
Assignee:
MEMORIAL SLOAN-KETTERING CANCER CENTER
Inventors:
Eric Pamer, Sohn Kim, Peter McKenney, Silvia Caballero
Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of Nectin-4. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by Nectin-4.
Type:
Grant
Filed:
June 20, 2019
Date of Patent:
November 23, 2021
Assignee:
BicycleTx Limited
Inventors:
Paul Beswick, Liuhong Chen, Gemma Mudd, Peter Park, Katerine Van Rietschoten, Michael Rigby
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating bone diseases comprising a fusion peptide in which a bone tissue-selective peptide bound to parathyroid hormone (PTH) or a fragment thereof. More particularly, the present invention relates to a pharmaceutical composition and biomaterial for preventing or treating bone diseases comprising a fusion peptide in which a bone tissue-selective peptide represented by an amino acid sequence of SEQ ID NO. 3 bound to parathyroid hormone (PTH) or a fragment thereof represented by an amino acid sequence of SEQ ID NO. 4 or 5. The fusion peptide can improve effects of PTH by selectively binding to bone tissue and can reduce administration frequency by increasing the half-life. The fusion peptide can be used as a subcutaneous or intravenous injection-type pharmaceutical composition for treating osteoporosis and fracture, and can be used in combination with a medical device for tissue recovery to increase formation of bone tissue.
Type:
Grant
Filed:
November 29, 2017
Date of Patent:
November 23, 2021
Assignees:
NANO INTELLIGENT BIOMEDICAL ENGINEERING CORPORATION CO. LTD., SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
Inventors:
Yoon Jeong Park, Chong-Pyoung Chung, Jue-Yeon Lee
Abstract: Aspects and embodiments of the present invention relate to the treatment of neurological disorders such as for example, Alzheimer's disease and Parkinson's disease. Particularly, certain embodiments relate to GIP/GLP-1 co-agonist peptides for use in the treatment of these two neurological disorders. Also included in the present invention are inter alia pharmaceutical compositions comprising the GIP/GLP-1 co-agonist peptides, together with methods of treating such disorders as well as other subject matter.
Type:
Grant
Filed:
December 4, 2017
Date of Patent:
November 16, 2021
Assignee:
Lancaster University Business Enterprises Limited
Abstract: The present invention relates to solid compositions for oral administration comprising (i) a GLP-1 derivative and the SGLT2 inhibitor dapagliflozin or (ii) a GLP-1 derivative and a salt of NAC in combination with an SGLT2 inhibitor.
Type:
Grant
Filed:
June 11, 2018
Date of Patent:
November 9, 2021
Assignee:
Novo Nordisk A/S
Inventors:
Andreas Vegge, Susanne Scheele, Simon Bjerregaard
Abstract: PYY analogs are disclosed that include modifications that increase half-life when compared to native, human PYY, as well as additional modifications that increase potency and selectivity to the NPY2 receptor. Pharmaceutical compositions also are disclosed that include one or more of the PYY analogs described herein in a pharmaceutically acceptable carrier. Methods of making and using the PYY analogs also are disclosed, especially for treating obesity and obesity-related diseases and disorders such as type II diabetes mellitus.
Type:
Grant
Filed:
October 28, 2019
Date of Patent:
October 26, 2021
Assignee:
Eli Lilly and Company
Inventors:
Daniel Anthony Briere, Daniel Christopher Lopes, Avinash Muppidi
Abstract: The present disclosure relates to a class of engineered polypeptides having a binding affinity for programmed death-ligand 1 (PD-L1), and provides a PD-L1 binding polypeptide comprising the sequence ERNX4AAX7EIL X11LPNLX16X17X18QX20 WAFIWX26LX28D. The present disclosure also relates to the use of such a PD-L1 binding polypeptide as a therapeutic, prognostic and/or diagnostic agent.
Abstract: The present invention provides a recombinant fusion protein. The fusion protein is formed by the fusion of D2 domain of Slit2 protein and HSA protein, and the position 386 amino acid of the Slit2 protein molecule is serine.
Type:
Grant
Filed:
November 21, 2019
Date of Patent:
October 19, 2021
Assignee:
ASCLEPIUS (SUZHOU) TECHNOLOGY COMPANY GROUP CO., LTD.
Abstract: A method of purifying an antifreeze protein (AFP) and methods of producing AFPs are disclosed. The method of purifying an AFP includes heating a crude AFP in an aqueous medium to a temperature and for a length of time sufficient to precipitate at least some thermally unstable proteins in the crude AFP and form a precipitate and a supernatant; and removing the precipitate from the supernatant. One method of producing an AFP includes collecting a crude source of the AFP; and purifying the AFP by the purification method. Another method of producing an AFP includes growing or culturing a host configured to express a recombinant AFP in a growth medium, and collecting a crude AFP from the host and/or the growth medium. The growth medium comprises water, a protein hydrolysate or other source of amino acids, a yeast extract, a biologically metabolizable C3-C6 polyol, and one or more phosphate salts.
Type:
Grant
Filed:
December 27, 2019
Date of Patent:
October 19, 2021
Assignees:
The Board of Trustees of the California State University, California State University, Los Angeles
Abstract: The present invention relates to a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF) capable of binding to blood coagulation Factor VIII (FVIII) for use in reducing the immunogenicity of Factor VIII (FVIII) wherein said recombinant polypeptide and a blood coagulation Factor VIII (FVIII) protein are co-administered to a subject suffering from a 10 blood coagulation disorder. The invention further relates to pharmaceutical compositions and kits for said use.
Type:
Grant
Filed:
June 22, 2018
Date of Patent:
October 12, 2021
Assignee:
CSL Behring Lengnau AG
Inventors:
Anne Verhagen, Sabine Pestel, Thomas Weimer, Marco Hofmann, Huy Huynh, Eugene Maraskovsky
Abstract: This invention relates to materials, such as peptides, and methods to inhibit the aggregation transcription factors, for example p53 inhibitors, p63 inhibitors and p73 inhibitors. More specifically, the invention relates to cancer chemotherapeutics. More specifically, the invention provides pharmaceutical compositions and methods of treating cancer with certain peptides.
Type:
Grant
Filed:
February 23, 2018
Date of Patent:
September 14, 2021
Assignee:
ADRX, INC.
Inventors:
Shiho Tanaka, Ashley Wright, James Treanor, Marcin Apostol
Abstract: Provided are methods for prophylaxis and/or therapy for Phelan-McDermid Syndrome (PMS) and autism spectrum disorder (ASD). The methods involve administering a histone methyltransferase (HMT) inhibitor, a histone deacetylase (HDAC) inhibitor, or a combination thereof, such that one or more symptoms of the PMS and/or the AMD are reduced.
Abstract: Novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies and have the general formula I: wherein R1, R2, R3, R4, R5 and R6 are as described herein.
Type:
Grant
Filed:
April 2, 2019
Date of Patent:
August 24, 2021
Assignee:
GENENTECH, INC.
Inventors:
Frederick Cohen, Lewis J. Gazzard, Vickie Hsiao-Wei Tsui, John A. Flygare
Abstract: The present invention provides a polyethylene glycol-modified endostatin analogue and an application thereof. The endostatin analogue is coupled to polyethylene glycol at lysine away from a nucleolin binding domain, or is coupled to polyethylene glycol at lysine away from a nucleolin binding domain and amidogen at the N end.
Abstract: The present invention has an object of providing a peptide synthesis method using a carrier capable of reversibly repeating the dissolved state and the insolubilized state, wherein the problem of an amino acid active species existing in the reaction system in de-protection reaction can be easily solved. The present invention provides a peptide synthesis method comprising the following steps: a step of condensing an N-Fmoc protected amino acid with a peptide having a C-terminal protected with a carrier which is crystallized according to a change of a composition of a dissolving solvent, in the presence of a condensing agent, to obtain an N-Fmoc-C-carrier protected peptide, a step of adding an alkylamine having 1 to 14 carbon atoms or hydroxyl amine to the reaction system, a step of de-protecting the N-terminal, and a step of changing the composition of the solvent dissolving the C-carrier protected peptide, to crystallize and separate the peptide.
Abstract: The present invention provides a conjugate comprising an albumin binding peptide and a cargo, compositions for directing cargos to the lymphatic system, and vaccines. The methods of the invention can be used to increase an immune response, or to treat cancer or an infectious disease.
Type:
Grant
Filed:
August 9, 2018
Date of Patent:
August 3, 2021
Assignee:
Massachusetts Institute of Technology
Inventors:
Kelly Dare Moynihan, Rebecca Lynn Holden, Darrell J. Irvine, Bradley Lether Pentelute
Abstract: Provided herein are compositions and methods for modulation of immune response via PYRIN domain-only proteins POP1 and/or POP3. In particular, POP1 and/or POP3 are inhibited to enhance an immune response (e.g., to treat or prevent infection), or POP1 and/or POP3 are administered or activated to reduce an immune response (e.g., to treat or prevent autoimmune or inflammatory disease).
Abstract: The present invention provides methods for treating disorders associated with intestinal barrier dysfunction and increased intestinal permeability. The invention involves administering an effective amount larazotide or a larazotide derivative to a subject or a patient in need thereof.
Type:
Grant
Filed:
February 12, 2018
Date of Patent:
July 13, 2021
Assignees:
9 METERS BIOPHARMA, INC., NORTH CAROLINA STATE UNIVERSITY
Inventors:
Jay P. Madan, Anthony Blikslager, Sandeep Laumas
Abstract: The invention pertains to novel hybrid peptidomimetics, pharmaceutical composition comprising thereof and use thereof in the treatment of neuropathic pain. The hybrid peptidomimetics according to the invention are comprised of two components: an opioid receptor agonist (OP) and a MC4 receptor antagonist, connected by a linker. The compounds of such a structure will allow to activate opioid receptors with simultaneous blocking of melanocortin type 4 receptors (MC4), which results in enhancing efficiency of the opioid therapy in neuropathic pain.
Type:
Grant
Filed:
July 3, 2018
Date of Patent:
June 22, 2021
Assignees:
Uniwersytet Warszawski, Instytut Farmakologii Polskiej Akademii Nauk
Inventors:
Aleksandra Misicka-Kesik, Ewa Witkowska, Beata Wilenska, Barbara Przewlocka, Joanna Mika, Joanna Starnowska-Sokol, Anna Piotrowska-Murzyn
Abstract: A method of isolating barrel-like proteases is disclosed. The method comprising isolating barrel-like proteases from a biological sample containing the barrel-like proteases under conditions that maintain the content of the barrel-like protease-processed peptides in the barrel-like proteases upon isolation. A method of isolating barrel-like protease-processed peptides and a method of identifying barrel-like protease-processed peptides are also disclosed.